Etravirine protects the activity of darunavir in the DUET trials by M Peeters et al.
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Etravirine protects the activity of darunavir in the DUET trials
M Peeters*1, J Vingerhoets1, L Tambuyzer1, H Azijn1, AM Hill2, S De Meyer1 
and G Picchio3
Address: 1Tibotec BVBA, Mechelen, Belgium, 2University of Liverpool, Liverpool, UK and 3Tibotec Inc, Yardley, USA
* Corresponding author    
Purpose of the study
It has been shown in the TITAN study that darunavir/
ritonavir (DRV/r) was more effective than lopinavir/riton-
avir in protecting against the emergence of NRTI muta-
tions. The protective effect of etravirine (ETR) on the
development of DRV resistance was studied in patients
experiencing virologic rebound in the ETR and placebo
arms of the DUET trials.
Methods
In this analysis, patients with a virologic rebound were
defined as those who showed a virologic response at ear-
lier time-points but rebounded to >50 copies/ml in the
DUET week 48 dataset. Phenotyping and genotyping at
baseline and end-point were performed with the Antiviro-
gram™ and Virco® TYPE HIV-1 assays, respectively, if viral
load (VL) was >1000 copies/ml. Emerging mutations were
those present at end-point (i.e. the last available resistance
test on treatment) but not at baseline. Patients who dis-
continued the trial for non-virologic reasons were
excluded.
Summary of results
Baseline DRV susceptibility was balanced across treatment
arms: overall median (range) number of primary protease
inhibitor (PI) mutations: 4 (0–8), DRV resistance associ-
ated mutations (RAMs): 2 (0–8), DRV fold change (FC):
6.40 (0.2–908.9), and 64% of patients had DRV FC ≤ 10
at baseline. ENF use and NRTI susceptibility were bal-
anced between arms.
Virologic rebound occurred in 57 (11%) and 119 (22%)
patients in the ETR and placebo arms, respectively.
Among those experiencing a rebound, fewer patients in
the ETR arm developed DRV RAMs (63% vs. 96% in pla-
cebo, p < 0.0001). The median number of emerging DRV
RAMs was one and two in the ETR and placebo arms,
respectively. The most frequently emerging DRV RAMs in
the ETR and placebo arms were V32I (32% vs. 60%), I54L
(16% vs. 34%) and I47V (11% vs. 8%). DRV FC at
rebound vs. baseline increased 2.8-fold and 10.1-fold in
the ETR and placebo arms, respectively (p < 0.0001).
Among the patients with virological rebound that had a
DRV FC ≤ 10 at baseline, 47% in the ETR arm vs. only 7%
in the placebo arm still had a DRV FC ≤ 10 at end-point.
Conclusion
In the DUET studies, ETR-treated patients experienced less
virologic rebound and loss of DRV susceptibility than
those in the placebo arm. Among those with virologic fail-
ure, ETR-treated patients showed less emergence of resist-
ance to DRV.
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